Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19134487 | 0.92 | ATM (0.58) | ATMELANETACR1CTSKCTRB1 | |
| SCHEMBL15936992 | 0.85 | ATM (0.51) | ATMELANETACR1CTSKCTSL | |
| SCHEMBL16847646 | 0.80 | ATM (0.68) | ATMELANETACR1CTSKPRTN3 | |
| SCHEMBL8295707 | 0.78 | ATM (0.57) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL16847645 | 0.77 | ATM (0.64) | ATMELANETACR1CTSKCTSL | |
| SCHEMBL17357789 | 0.77 | ATM (0.52) | ATMTACR1CTRB1CTSLCTSS | |
| SCHEMBL7329364 | 0.77 | ATM (0.57) | ATMELANETACR1CTSKPRTN3 | |
| SCHEMBL16829101 | 0.76 | ATM (0.53) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL21048451 | 0.76 | ATM (0.53) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL19388339 | 0.75 | ATM (0.55) | ATMELANETACR1CTSKPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885ELANE 4270/4885TACR1 41/4885 |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885ELANE 4270/4885TACR1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.